TY  - JOUR 
AU  - Santaliestra, Marta
AU  - Garrote, Marta
AU  - Noya Pereira, María Soledad
AU  - Pérez Encinas, Manuel Mateo
AU  - Senín, Alicia
AU  - Pérez-López, Raúl
AU  - Ferrer-Marín, Francisca
AU  - Carreño-Tarragona, Gonzalo
AU  - Caballero, Gonzalo
AU  - Magro, Elena
AU  - Vélez, Patricia
AU  - Cortés Vázquez, Miguel Ángel
AU  - Moretó, Ana
AU  - Angona, Anna
AU  - Pastor-Galán, Irene
AU  - Guerra, José María
AU  - García Hernández, Carmen
AU  - Mata, María Isabel
AU  - Stuckey, Ruth
AU  - Gómez-Casares, María Teresa
AU  - Fox, Laura
AU  - Cuevas, Beatriz
AU  - García-Gutiérrez, Valentín
AU  - Triguero, Ana
AU  - Arellano-Rodrigo, Eduardo
AU  - Hernández-Boluda, Juan Carlos
AU  - Alvarez-Larrán, Alberto
PY  - 2024
UR  - http://hdl.handle.net/20.500.11940/22285
AB  - [EN] Hydroxyurea (HU) constitutes the first-line treatment in most patients with essential thrombocythemia (ET), but criteria for changing therapy are not clearly established. The prognostic value of complete hematological response (CHR) and...
LA  - eng
KW  - Hydroxyurea
KW  - Prognosis
KW  - Risk Factors
KW  - Thrombosis
TI  - Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
DO  - 10.1038/s41375-024-02416-2
T2  - Leukemia
M2  - 2636
KW  - CHUAC
KW  - CHUS
VL  - 38
ER  -